XML 34 R40.htm IDEA: XBRL DOCUMENT v3.2.0.727
Collaborative Arrangement - Additional Information (Detail) - Entity [Domain]
$ in Thousands
3 Months Ended 6 Months Ended
Aug. 10, 2015
USD ($)
Jul. 28, 2015
USD ($)
Sep. 23, 2014
USD ($)
Aug. 11, 2014
USD ($)
Mar. 31, 2015
USD ($)
Contract
Sep. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred cost             $ 10,831
License and Collaboration Agreement with Sanofi              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Up-front fee           $ 150,000  
Potential milestone payment       $ 725,000     $ 725,000
Profits and losses sharing percentage       35.00%     35.00%
Maximum secured loan facility     $ 175,000        
Senior notes, effective interest rate     8.50%        
Prepayment of loan percentage of net cash proceeds sale     100.00%        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmnH              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Profits and losses sharing percentage       65.00%     65.00%
Deferred revenue from collaboration product shipments             $ 150,000
Milestone receivable             50,000
Deferred cost             10,800
Loss sharing amount reclassified to loan facility and loss share obligation         $ 12,400   12,800
Maximum secured loan facility             175,000
Secured loan facility, amount borrowed             15,600
Paid-in-kind interest             200
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmnH | Subsequent Event              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Secured loan facility, amount borrowed   $ 12,800          
Secured loan facility, amount owed $ 28,400            
Paid-in-kind interest $ 200            
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmnH | AFREZZA product sales              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred revenue from collaboration product shipments             $ 13,400
License and Collaboration Agreement with Sanofi | Manufacturing Milestone Events              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Milestone payments earned         $ 50,000    
Number of milestones achieved | Contract         2    
License and Collaboration Agreement with Sanofi | Development Milestone Event              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payment       $ 25,000      
License and Collaboration Agreement with Sanofi | Regulatory Approvals              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payment       50,000      
License and Collaboration Agreement with Sanofi | Product Sales Milestones              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payment       $ 650,000